© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
CDT Equity Inc. (CDT) stock declined over -42.54%, trading at $0.34 on NASDAQ, down from the previous close of $0.60. The stock opened at $0.41, fluctuating between $0.33 and $0.41 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 0.41 | 0.41 | 0.33 | 0.34 | 42.45M |
| Sep 09, 2026 | 0.60 | 0.62 | 0.58 | 0.60 | 122.8K |
| Sep 08, 2026 | 0.60 | 0.66 | 0.58 | 0.62 | 298.05K |
| Sep 04, 2026 | 0.73 | 0.75 | 0.61 | 0.63 | 727.29K |
| Sep 03, 2026 | 0.88 | 0.89 | 0.70 | 0.75 | 0 |
| Sep 02, 2026 | 1.15 | 1.20 | 0.90 | 0.91 | 1.24M |
| Sep 01, 2026 | 1.70 | 1.71 | 1.40 | 1.48 | 2.42M |
| Aug 31, 2026 | 1.71 | 1.79 | 1.60 | 1.68 | 135.85K |
| Aug 28, 2026 | 1.98 | 2.03 | 1.62 | 1.69 | 485.62K |
| Aug 27, 2026 | 1.89 | 1.97 | 1.80 | 1.88 | 151.17K |
| Aug 26, 2026 | 2.11 | 2.11 | 1.82 | 1.89 | 92.7K |
| Aug 25, 2026 | 2.41 | 2.45 | 1.92 | 2.05 | 499.26K |
| Aug 24, 2026 | 2.95 | 2.98 | 2.46 | 2.49 | 57.47K |
| Aug 21, 2026 | 2.99 | 3.40 | 2.84 | 2.86 | 80.63K |
| Aug 20, 2026 | 2.96 | 3.01 | 2.82 | 2.90 | 28.05K |
| Aug 19, 2026 | 2.97 | 3.06 | 2.93 | 3.01 | 27.15K |
| Aug 18, 2026 | 2.75 | 3.02 | 2.66 | 2.89 | 27.27K |
| Aug 17, 2026 | 2.87 | 3.05 | 2.80 | 2.80 | 33.09K |
| Aug 14, 2026 | 2.97 | 3.08 | 2.80 | 2.92 | 28.22K |
| Aug 13, 2026 | 3.04 | 3.25 | 3.04 | 3.15 | 34.21K |
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
| Employees | 4 |
| Beta | 1.49 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |